BMN-673 enantiomer
| Key | Value |
|---|---|
| Synonyms: | 1207456-01-6 BMN 673 BMN-673 TALAZOPARIB UNII-9QHX048FRV 765396 727125 BMN-673 (RACEMATE) LT-00673 BMN-673 (RACEMIC) 767125 |
| National Service Center# (NSC#):1,2 | 767533, 767125, 765396 |
| CAS#: | NA |
| PubChem Substance#: | 440798925 |
| PubChem Compound#: | 135742498 |
| Mechanism of Action: | PARP1 |
| Status: | Clinical trial |
| Molecular Formula: | C19H14F2N6O |
| Smiles: | Cn1ncnc1[C@H]2[C@@H](Nc3cc(F)cc4C(=O)NN=C2c34)c5ccc(F)cc5 |
BMN-673 enantiomer is in CellMinerCDB, a searchable tool integrating cancer cell line pharmacogenomics data to link gene and drug activity signatures.
Click Here to Access CellMinerCDB
BMN-673 enantiomer is in CellMiner (NCI-60),a database and query tool designed for the cancer research community to facilitate integration and study of molecular and pharmacological data for the NCI-60 cancerous cell lines.
Click Here to Access CellMiner (NCI-60)
If you use content from this page, CellMinerCDB or CellMiner (NCI-60), please cite: Luna A et al. 2021. PMID: 33196823, Rajapakse VN et al. 2018. PMID: 30553813, Luna et al. 2016., PMID: 26635141, and Reinhold et al. 2012., PMID: 22802077.
Available Data
Visit CellMinerCDB to interactively explore available pharmacogenomics data for BMN-673 enantiomer.
Visit CellMiner (NCI-60) to explore NCI-60 related analysis for BMN-673 enantiomer.
| NCI60 | HTS384 NCI60 | GDSC-MGH-Sanger | GDSC1 drugs | GDSC2 drugs | CCLE-Broad-MIT | CTRP-Broad-MIT | NCI-DTP SCLC | PRISM-Broad-MIT | NCI60-DTP Almanac | NCATS IC50 | NCATS AUC |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 765396 727125 767125 |
765396 767125 |
BMN-673 | Talazoparib | Talazoparib | NA | NA | 765396 767125 767533 |
talazoparib | NA | talazoparib | talazoparib |
2 Most structures have a unique NSC number but over the years a small percentage of structures or agents may have been assigned more than one NSC number. In the case of salts, different salt forms (e.g. HCl, HOAc) are designated with separate NSC numbers.
